These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18991236)

  • 1. [Topiramate augmentation in treatment-resistant obsessive-compulsive disorder].
    Vinkers DJ; van der Wee NJ
    Tijdschr Psychiatr; 2008; 50(11):747-50. PubMed ID: 18991236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder.
    Hollander E; Dell'Osso B
    Int Clin Psychopharmacol; 2006 May; 21(3):189-91. PubMed ID: 16528143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
    Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E
    J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series.
    Van Ameringen M; Mancini C; Patterson B; Bennett M
    Depress Anxiety; 2006; 23(1):1-5. PubMed ID: 16178009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of riluzole augmentation in a patient with treatment-resistant obsessive-compulsive disorder, taking two other glutaminergic agents.
    Mahgoub N; Asemota B; Alexopoulos GS
    J Neuropsychiatry Clin Neurosci; 2011; 23(2):E24-5. PubMed ID: 21677213
    [No Abstract]   [Full Text] [Related]  

  • 6. Topiramate related obsessive-compulsive disorder.
    Ozkara C; Ozmen M; Erdogan A; Yalug I
    Eur Psychiatry; 2005 Jan; 20(1):78-9. PubMed ID: 15642451
    [No Abstract]   [Full Text] [Related]  

  • 7. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial.
    Sahraian A; Bigdeli M; Ghanizadeh A; Akhondzadeh S
    J Affect Disord; 2014 Sep; 166():201-5. PubMed ID: 25012432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topiramate augmentation in a patient with obsessive-compulsive disorder.
    Van Ameringen M; Patterson B
    J Psychiatry Neurosci; 2015 Sep; 40(5):E31-2. PubMed ID: 26290064
    [No Abstract]   [Full Text] [Related]  

  • 9. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
    Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
    Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compulsive buying treatment with topiramate, a case report.
    Guzman CS; Filomensky T; Tavares H
    Braz J Psychiatry; 2007 Dec; 29(4):383-4. PubMed ID: 18200404
    [No Abstract]   [Full Text] [Related]  

  • 11. The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder.
    Rubio G; Jiménez-Arriero MA; Martínez-Gras I; Manzanares J; Palomo T
    J Clin Psychopharmacol; 2006 Jun; 26(3):341-4. PubMed ID: 16702907
    [No Abstract]   [Full Text] [Related]  

  • 12. Compulsive skin manipulation treated by topiramate.
    Ye L; Bawa R; Lippmann S
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):369-70. PubMed ID: 23782131
    [No Abstract]   [Full Text] [Related]  

  • 13. Topiramate-induced psychosis.
    Kober D; Gabbard GO
    Am J Psychiatry; 2005 Aug; 162(8):1542. PubMed ID: 16055782
    [No Abstract]   [Full Text] [Related]  

  • 14. Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report.
    Uzun O
    J Psychopharmacol; 2010 Mar; 24(3):425-7. PubMed ID: 19010977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.
    Pittenger C; Krystal JH; Coric V
    NeuroRx; 2006 Jan; 3(1):69-81. PubMed ID: 16490414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topiramate and compulsive buying disorder.
    Ye L; Kadia S; Lippmann S
    J Clin Psychopharmacol; 2014 Feb; 34(1):174-5. PubMed ID: 24346750
    [No Abstract]   [Full Text] [Related]  

  • 17. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
    Coric V; Taskiran S; Pittenger C; Wasylink S; Mathalon DH; Valentine G; Saksa J; Wu YT; Gueorguieva R; Sanacora G; Malison RT; Krystal JH
    Biol Psychiatry; 2005 Sep; 58(5):424-8. PubMed ID: 15993857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine augmentation for refractory obsessive-compulsive disorder.
    Pasquini M; Biondi M
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1173-5. PubMed ID: 16730870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of anticonvulsants in the treatment of obsessive-compulsive and related disorders.
    Wang HR; Woo YS; Bahk WM
    Psychiatry Clin Neurosci; 2014 Oct; 68(10):723-32. PubMed ID: 24735021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
    Feusner JD; Kerwin L; Saxena S; Bystritsky A
    Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.